Trial Profile
Favipiravir for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms PRESECO
- Sponsors Appili Therapeutics
- 29 Nov 2021 Status changed from active, no longer recruiting to completed.
- 12 Nov 2021 According to an Aditxt media release, additional analyses of the trial data of this study is ongoing.
- 12 Nov 2021 Primary endpoint (Time to sustained clinical recovery) has not been met, according to an Appili Therapeutics media release.